Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2009

View Archived Issues

Novel PIM kinase inhibitors for cancer treatment claimed by scientists at CNIO

Ampla Pharmaceuticals patents novel CB1/GLP-1 receptor ligands

PharmacoFore discloses novel mu-opioid receptor antagonists for the treatment of constipation

Access reports preclinical data from therapeutic study of thiarabine in RA

Prepandemic vaccine strategy may allow boosting years later for influenza control

GTC obtains exclusive worldwide rights to rhAFP and MM-093 from Merrimack

Endo licenses exclusive rights to develop and market Urocidin from Bioniche

Tamsulosin associated with postoperative cataract surgery complications

Johnson & Johnson acquires Cougar Biotechnology, strengthens position in oncology market

Sciele Pharma and Victory Pharma mutually agree to terminate merger agreement

CytRx's INNO-206 demonstrates tumor shrinkage in animal breast cancer model

Hutchinson MediPharma reports phase II results for HMPL-004 in Crohn's disease

F2G commences phase I trial for antifungal drug candidate, FG-3622

NovImmune completes NI-0801 phase I clinical study

Medarex to receive milestone payment from FibroGen for phase II FG-3019 trial

RECORD4 study shows rivaroxaban superior to enoxaparin in knee surgery thromboprophylaxis

Rituximab efficacy largely transient in pediatric steroid-dependent nephrotic syndrome

Modest activity seen with ixabepilone in previously treated endometrial cancer

Abraxis completes enrollment in phase III clinical study of Abraxane in NSCLC

FX-125L shows efficacy in model of allergic asthma, enters phase I study

Cancer Research Technology part of new alliance to discover WNT pathway inhibitors

Oxford BioMedica reports update on phase I/II study of ProSavin gene therapy in PD

Daiichi Sankyo and Lilly receive FDA approval for Effient for thrombosis

AMAG launches Feraheme injection in the U.S. for anemia

FDA accepts Victory Pharma's MGX-006 NDA for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...